GW&K Investment Management Reduces Stake in Supernus Pharmaceuticals

The investment firm sold 184,268 shares of the specialty pharmaceutical company in the third quarter.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

GW&K Investment Management LLC reduced its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 14.6% during the third quarter, according to a recent SEC filing. The firm now owns 1,080,538 shares of the specialty pharmaceutical company's stock, worth approximately $51.6 million.

Why it matters

Supernus Pharmaceuticals is a key player in the specialty pharmaceutical industry, focused on developing and commercializing central nervous system therapies. Changes in major institutional investors' holdings can signal shifts in market sentiment and influence the stock's performance.

The details

According to the filing, GW&K Investment Management sold 184,268 shares of Supernus Pharmaceuticals during the third quarter. The firm now owns about 1.88% of the company's outstanding shares. Supernus Pharmaceuticals' stock price has fluctuated in recent months, trading between $29.16 and $59.68 over the past year.

  • GW&K Investment Management reduced its Supernus Pharmaceuticals holdings during the third quarter of 2025.

The players

GW&K Investment Management LLC

An investment management firm that previously held a significant stake in Supernus Pharmaceuticals.

Supernus Pharmaceuticals, Inc.

A specialty pharmaceutical company focused on developing and commercializing central nervous system therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in GW&K Investment Management's position in Supernus Pharmaceuticals could signal a shift in market sentiment around the specialty pharmaceutical company, though the overall fundamentals of the business remain strong.